Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Viveve Medical, Inc. (VIVE : NSDQ)
 
 • Company Description   
Viveve Medical, Inc. is a medical device company focused on technologies for the cardiac and vascular markets. The Company's lead product, RenalGuard (R), is designed to remove contrast dyes that are known to be toxic to the kidneys. Viveve Medical Inc., formerly known as PLC Systems Inc., is headquartered in Milford, Massachusetts.

Number of Employees: 47

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.78 Daily Weekly Monthly
20 Day Moving Average: 35,419 shares
Shares Outstanding: 10.64 (millions)
Market Capitalization: $8.30 (millions)
Beta: 0.64
52 Week High: $3.22
52 Week Low: $0.74
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -25.00% -18.13%
12 Week -15.62% -8.81%
Year To Date -31.58% -18.96%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
345 INVERNESS DRIVE SOUTH BUILDING B SUITE 250
-
ENGLEWOOD,CO 80112
USA
ph: 720-696-8100
fax: 720-696-8199
ir@viveve.com http://www.viveve.com
 
 • General Corporate Information   
Officers
Scott Durbin - Chief Executive Officer and Director
Steven Basta - Chairman
Jim Robbins - Principal Accounting and Financial Officer
Debora Jorn - Director
Arlene Morris - Director

Peer Information
Viveve Medical, Inc. (ABMD)
Viveve Medical, Inc. (DMDS)
Viveve Medical, Inc. (CPWY.)
Viveve Medical, Inc. (EQUR)
Viveve Medical, Inc. (ECIA)
Viveve Medical, Inc. (FMS)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED INSTRUMENTS
Sector: Medical
CUSIP: 92852W501
SIC: 3845
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 10.64
Most Recent Split Date: 12.00 (0.10:1)
Beta: 0.64
Market Capitalization: $8.30 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.36 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.82
Price/Cash Flow: -
Price / Sales: 1.25
EPS Growth
vs. Year Ago Period: 16.25%
vs. Previous Quarter: 6.94%
Sales Growth
vs. Year Ago Period: 13.17%
vs. Previous Quarter: -3.81%
ROE
03/31/22 - -132.32
12/31/21 - -105.11
09/30/21 - -107.57
ROA
03/31/22 - -84.27
12/31/21 - -72.33
09/30/21 - -72.49
Current Ratio
03/31/22 - 1.71
12/31/21 - 4.91
09/30/21 - 7.12
Quick Ratio
03/31/22 - 1.55
12/31/21 - 4.58
09/30/21 - 6.56
Operating Margin
03/31/22 - -353.45
12/31/21 - -360.19
09/30/21 - -322.68
Net Margin
03/31/22 - -353.45
12/31/21 - -360.19
09/30/21 - -323.58
Pre-Tax Margin
03/31/22 - -329.76
12/31/21 - -338.80
09/30/21 - -303.08
Book Value
03/31/22 - 0.96
12/31/21 - 1.42
09/30/21 - 1.92
Inventory Turnover
03/31/22 - 3.10
12/31/21 - 2.50
09/30/21 - 2.08
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.34
09/30/21 - 0.24
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 25.38
09/30/21 - 19.60
 

Powered by Zacks Investment Research ©